Bristol Myers: positive results from phase III trial
Dual immunotherapy combining Opdivo and Yervoy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), with a 79% reduction in the risk of disease progression or death compared to chemotherapy.
These late-breaking data were presented at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal Cancers Symposium on Saturday, January 20.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction